Pharma News

Dr Reddy’s barred from selling Esomeprazole Capsules in the US : Dr Reddy’s has received a Temporary Restraining Order (TRO) for Esomeprazole Capsules . The District Court of Delaware, USA, has passed an order granting a Temporary Restraining Order (TRO) with immediate effect on sales, delivery, transfer, or other disposition of Dr Reddy’s Laboratories’ generic esomeprazole product in the US ... Read More »

Arogya Finance and DRL collaborate to provide medical loans for financially weak Facilitates medical loans for Resof, a drug for treatment of Hepatitis C virus (HCV) infection and a few other therapies Arogya Finance has tied up with Dr Reddy’s Laboratories for providing medical loans for treatment of Hepatitis C. Reportedly, Arogya Finance will facilitate easy Equated Monthly Installments to patients ... Read More »

Torrent Pharma’s new Dahej plant commences operations The plant will mainly cater to the more regulated international markets such as the US, Brazil and Germany Torrent Pharma has commenced commercial operations at its new plant in Dahej. This is the company’s fifth formulation plant and the second API plant. The facility is being set up in two phases. The total investment ... Read More »

IIL opens ‘New Bovine Serum’ manufacturing unit in New Zealand The new plant can manufacture up to 300 tonnes of serum Indian Immunologicals Limited (IIL) has recently inaugurated its ‘New Bovine Serum’ manufacturing plant in New Zealand. The plant will produce key products like new born calf serum, adult bovine serum (NZ origin) and bulk bovine haemoglobin (NZ origin) for bio-pharmaceutical, ... Read More »

Alkem Laboratories gets SEBI’s nod for IPO As per the draft papers, the company will come out with a public offer of up to 12,853,442 equity shares Alkem Laboratories has received capital markets regulator Securities and Exchange Board of India’s (Sebi) approval to raise an estimated Rs 1,500-3,500-crore through an initial public offering (IPO). Alkem Laboratories filed the Draft Red Herring ... Read More »

GSK exercises option for inhaled therapeutics from Liquidia Technologies GlaxoSmithKline (GSK) has exercised an option that gives it the exclusive rights to research, develop and commercialize inhaled therapeutics derived from Liquidia Technologies’ PRINT technology. Under a collaboration and option agreement signed in June 2012, Liquidia was entitled to receive an upfront payment including cash and equity, R&D funding, and possible ... Read More »

Torrent Pharma board approves Zyg Pharma’s amalgamation It will result in concentrated management focus and synergies of operations and facilitating inter transfer of resources and optimum utilisation of assets Torrent Pharmaceuticals’ board has given nod to the scheme of amalgamation of its subsidiary Zyg Pharma with the company. The Board of Directors of the company “has approved the scheme of amalgamation ... Read More »

Siemens Healthcare joins CANCER-ID Siemens Healthcare has joined the CANCER-ID consortium, an initiative of the European Union’s Innovative Medicines Initiative (IMI), to explore the potential of blood-based biomarkers to revolutionize the detection and treatment of cancer. This consortium currently includes 33 partners from 13 countries working together to establish standard protocols for the clinical validation of blood-based biomarkers. These biomarkers, ... Read More »

GlaxoSmithKline Pharmaceuticals acquires the Vaccines business of Novartis and divests its Oncology business to Novartis GlaxoSmithKline Pharmaceuticals (‘GSK India’) announces completion of its transaction with Novartis Healthcare (‘Novartis India’), where GSK India acquires Novartis’ vaccines business and divests its marketed oncology portfolio to Novartis India. This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) ... Read More »

Dr Reddy’s launch new generic in the US Dr Reddy’s announces the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg Dr Reddy’s Laboratories has announced that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg in the US market, following the approval by the United States Food and Drug Administration (US FDA). ... Read More »